Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 9—September 2009
Dispatch

Population-based Surveillance for Hepatitis C Virus, United States, 2006–2007

R. Monina KlevensComments to Author , Jeremy Miller, Candace Vonderwahl, Suzanne Speers, Karen Alelis, Kristin Sweet, Elena Rocchio, Tasha Poissant, Tara M. Vogt, and Kathleen Gallagher
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.M. Klevens, J. Miller, T.M. Vogt, K. Gallagher); Colorado Department of Health, Denver, Colorado, USA (C. Vonderwahl); Connecticut Department of Public Health, Hartford, Connecticut, USA (S. Speers); Florida Health Department of Pinellas County, St. Petersburg, Florida, USA (K. Alelis); Minnesota Department of Health, St. Paul, Minnesota, USA (K. Sweet); New York State Department of Health, Albany, New York, USA (E. Rocchio); Oregon Public Health Division, Portland, Oregon, USA (T. Poissant)

Main Article

Table

Newly reported cases of past or present HCV infection in 6 US locations, July 1, 2006–June 30, 2007*†

Characteristic Colorado Connecticut Minnesota New York‡ Oregon Pinellas County, Florida Total
Estimated population, 2007 4,862,000 3,502,000 5,198,000 11,068,000 3,747,000 924,000 29,301,000
Year registry initiated
1993
1994
1998
2003
2005
1999

Sex, no. (%)
F 1,088 (36.5) 1,360 (35.9) 494 (37.6) 2,882 (30.4) 711 (34.9) 302 (45.4) 6,837 (33.8)
M 1,879 (63.0) 2,429 (64.1) 804 (61.2) 6,595 (69.5) 1,285 (63.0) 359 (54.0) 13,351 (66.0)
Unknown
16 (0.5)
3 (0.1)
15 (1.1)
15 (0.2)
44 (2.2)
4 (0.6)
53 (0.3)
Age group, y, no. (%)
0–14 16 (0.5) 9 (0.2) 10 (0.8) 14 (0.2) 9 (0.4) 5 (0.8) 63 (0.3)
15–24 126 (4.2) 127 (3.4) 37 (2.8) 318 (3.4) 55 (2.7) 25 (3.8) 688 (3.4)
25–39 638 (21.4) 741 (19.5) 200 (15.2) 1,527 (16.1) 386 (18.9) 69 (10.4) 3,561 (17.6)
40–54 1,645 (55.2) 2,158 (56.9) 798 (60.8) 5,153 (54.3) 1,149 (56.3) 411 (61.8) 11,314 (56.0)
>55 546 (18.3) 755 (19.9) 267 (20.3) 2,438 (25.7) 422 (20.7) 155 (23.3) 4,583 (22.7)
Unknown
12 (0.4)
2 (0.0)
1 (0.1)
42 (0.4)
19 (0.9)
0
76 (0.4)
Case criteria, no. (%)§
Anti-HCV and supplemental 
 test 593 (19.9) 1,520 (40.1) 520 (39.6) 3,763 (39.6) 203 (10.0) 0 6,599 (32.5)
RIBA 527 (17.7) 466 (12.3) 384 (29.3) 1,404 (14.8) 185 (9.1) 15 (2.3) 2,981 (14.7)
HCV RNA 1,245 (41.7) 1,984 (52.3) 928 (70.7) 5,831 (61.4) 818 (40.1) 28 (4.2) 10,834 (53.4)
Genotype 586 (19.6) 21 (0.6) 304 (23.2) 1,473 (15.5) 207 (10.2) 142 (21.4) 2,733 (13.5)
Anti-HCV and s:co ratio
1,859 (62.3)
1,352 (35.7)
253 (19.3)
4,709 (49.6)
905 (44.4)
521 (78.4)
9,599 (47.3)
Source of report, no. (%)
Laboratory 2,561 (85.9) 3,792 (100.0) 878 (66.9) 8,252 (86.9) 1,923 (94.3) 592 (89.0) 17,998 (88.7)
Others, combined¶
422 (14.2)
0
435 (33.1)
1,240 (13.1)
117 (5.7)
73 (11.0)
2,287 (11.3)
Total reports 2,983 3,792 1,313 9,492 2,040 665 20,285
Report rate/100,000 population 61.4 108.3 25.3 85.8 54.4 71.9 69.2

*HCV, hepatitis C virus; RIBA, recombinant immunoblot assay; anti-HCV, antibodies against HCV; s:co, signal-to-cutoff.
†A confirmed case requires laboratory confirmation. Laboratory criteria consist of at least 1 of the following: a positive result for a HCV RIBA, a positive result for a nucleic acid test for HCV RNA, an HCV genotype, or enzyme immunoassay with detection of anti-HCV and a s:co ratio predictive of a true positive result for a particular assay (see www.cdc.gov/ncphi/disss/nndss/casedef/hepatitisccurrent.htm for the 2005 Council of State and Territorial Epidemiologists/Centers for Disease Control and Prevention case definition).
‡Excludes New York, New York.
§Cases could be reported with more than minimum laboratory criteria; totals add up to >100%.
¶Other sources of reports included private healthcare providers, facilities such as hospitals and outpatient clinics, and institutions such as prisons, blood banks, and drug treatment centers, among others.

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external